Description
Snap-8 is a synthetic octapeptide with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH₂, developed by Lipotec SA as an extended analog of Argireline (acetyl hexapeptide-3). The two additional C-terminal residues — Ala-Asp — extend the sequence to eight amino acids and improve SNARE complex binding interaction relative to the six-residue parent. Snap-8 is a competitive inhibitor of SNARE complex assembly. It mimics the N-terminal SNAP-25 protein fragment and competes with endogenous SNAP-25 for syntaxin-1 binding sites — the initial contact step in SNARE complex formation. This competition reduces vesicle fusion efficiency at the neuromuscular junction and attenuates acetylcholine release per action potential. Researchers studying specialty research peptide neuromuscular signaling and SNARE-mediated exocytosis use Snap-8 as a tool for probing SNARE complex assembly without the irreversible cleavage associated with botulinum toxin approaches.
Key Characteristics
- Competitive inhibition mechanism is reversible and partial — Snap-8 reduces SNARE complex formation efficiency by occupying syntaxin-1 binding sites, but does not cleave or permanently inactivate SNARE proteins; this distinguishes it mechanistically from botulinum toxin, which irreversibly cleaves SNAP-25, and makes it appropriate for research designs requiring recoverable neuromuscular junction function
- Two-residue extension from Argireline improves binding — the Ala-Asp extension beyond the hexapeptide core provides additional contact with the SNARE complex assembly site; researchers comparing SNARE inhibition across peptide length variants use Snap-8 alongside Argireline in SAR studies examining how sequence extension affects competitive binding efficiency
- N-terminal acetylation and C-terminal amidation protect both termini from exopeptidase degradation — the same dual modification strategy seen in the N-Acetyl peptide variants in this catalog; for Snap-8, these modifications are intrinsic to the compound’s defined structure rather than optional analog variants
- Unlike BPC-157, which is studied for angiogenic and extracellular matrix signaling in tissue models, Snap-8 operates at the presynaptic neuromuscular junction level — a different layer of tissue biology, despite both being studied in dermal and connective tissue research contexts
- Catecholamine release modulation has been documented alongside acetylcholine inhibition — dopamine, norepinephrine, and epinephrine vesicle fusion is also attenuated, suggesting SNARE complex involvement in catecholaminergic neurotransmission is a secondary research angle for this compound
Handling and Storage
Store as lyophilized powder under refrigeration, away from heat, moisture, and light. The dual terminal modifications improve stability. Reconstitute immediately before use and avoid repeated freeze-thaw cycles.
FAQs
What is Snap-8?
Snap-8 (Acetyl Octapeptide-3) is a synthetic eight-amino-acid peptide that mimics the N-terminal fragment of SNAP-25 — one of the three core SNARE complex proteins — and competitively inhibits SNARE complex assembly at neuromuscular junctions. It reduces acetylcholine vesicle fusion efficiency by competing with endogenous SNAP-25 for syntaxin-1 binding sites. The inhibition is competitive and reversible, not permanent.
How does Snap-8 differ from Argireline in SNARE research models?
Argireline (acetyl hexapeptide-3) and Snap-8 share the same six N-terminal amino acids and the same competitive SNARE inhibition mechanism. Snap-8 extends the sequence by two additional residues at the C-terminus (Ala-Asp), which improves contact with the SNARE complex assembly site and competitive binding efficiency. Researchers studying SNARE peptide inhibitor structure-activity relationships use both compounds to examine how sequence length affects competitive inhibition potency and binding specificity.
Why is SNARE complex competitive inhibition a research-relevant mechanism beyond its primary application?
SNARE proteins govern vesicular exocytosis across many cell types — not only at the neuromuscular junction. SNARE-mediated vesicle fusion is involved in insulin secretion, immune cell degranulation, and neurotransmitter release in CNS synapses. Snap-8’s competitive inhibition mechanism makes it a tool for probing SNARE complex assembly dynamics in these broader contexts, not only in dermal neuromuscular junction models.
